Evaluation of SPIO-Enhanced MRI in Distinguishing Metastatic Lymph Nodes from Reactive Hyperplasia in Breast Cancer: Diagnostic Efficacy and Correlation with VEGF-C Levels - Takeaways - MDSpire

Evaluation of SPIO-Enhanced MRI in Distinguishing Metastatic Lymph Nodes from Reactive Hyperplasia in Breast Cancer: Diagnostic Efficacy and Correlation with VEGF-C Levels

  • By

  • Tao Wu

  • Angela Wu

  • Hui Xiong

  • Jiaying Deng

  • Zhewen Zhang

  • Dan Gong

  • Jun Luo

  • Dan Wu

  • April 22, 2026

  • 0 min

Share

  • 1

    SPIO-enhanced MRI effectively differentiates metastatic lymph nodes from reactive hyperplastic nodes in breast cancer patients.

  • 2

    The study involved 60 patients and analyzed 112 lymph nodes, revealing significant differences in signal intensity loss between node types.

  • 3

    SPIO-enhanced MRI achieved an overall diagnostic accuracy of 84%, with sensitivity of 83% and specificity of 85% at an optimal PSIL cutoff.

  • 4

    High VEGF-C expression was significantly more prevalent in metastatic nodes, correlating with imaging characteristics observed in SPIO-MRI.

  • 5

    The findings support the potential of SPIO-enhanced MRI for non-invasive lymph node assessment, warranting further validation in larger studies.

Original Source(s)

Evaluation of SPIO-Enhanced MRI in Distinguishing Metastatic Lymph Nodes from Reactive Hyperplasia in Breast Cancer: Diagnostic Efficacy and Correlation with VEGF-C Levels

  • by Tao Wu, Angela Wu, Hui Xiong, Jiaying Deng, Zhewen Zhang, Dan Gong, Jun Luo, Dan Wu

  • April 22, 2026

Related Content

Successful reversal of hepatic visceral crisis in HER2-positive metastatic breast cancer: a case report

Correction: Regulatory actions of LH and follicle-stimulating hormone on breast cancer cells and mammary tumors in rats

Effects of SOX10 on the proliferative, invasive, migratory, and epithelial–mesenchymal transition abilities of triple-negative breast cancer cells